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Fabry disease is a rare, X-linked, lysosomal storage disease caused by mutations in the gene encoding the enzyme
alpha-galactosidase A. Complete or partial deficiency in this enzyme leads to intracellular accumulation of
globotriaosylceramide (Gb3) and related glycosphingolipids in many cell types throughout the body, including the
kidney. Progressive accumulation of Gb3 in podocytes, epithelial cells and the tubular cells of the distal tubule and loop
of Henle contribute to the renal symptoms of Fabry disease, which manifest as proteinuria and reduced glomerular
filtration rate leading to chronic kidney disease and progression to end-stage renal disease. Early diagnosis and
timely initiation of treatment of Fabry renal disease is an important facet of disease management. Initiating
treatment with enzyme replacement therapy (ERT; agalsidase alfa, Replagal®, Shire; agalsidase beta, Fabrazyme®,
Genzyme) as part of a comprehensive strategy to prevent complications of the disease, may be beneficial in stabilizing
renal function or slowing its decline. Early initiation of ERT may also be more effective than initiating therapy in patients
with more advanced disease. Several strategies are required to complement the use of ERT and treat the myriad of
associated symptoms and organ involvements. In particular, patients with renal Fabry disease are at risk of cardiovascular
events, such as high blood pressure, cardiac arrhythmias and stroke. This review discusses the management of
renal involvement in Fabry disease, including diagnosis, treatments, and follow-up, and explores recent advances
in the use of biomarkers to assist with diagnosis, monitoring disease progression and response to treatment.
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Fabry disease is a rare, X-linked, lysosomal storage dis-
ease (OMIM #301500) caused by mutations in the gene
encoding the acid hydrolase enzyme alpha-galactosidase
A (EC 3.2.1.22), which catalyses removal of a galactose
moiety from neutral sphyngolipids, predominantly globo-
triaosylceramide (Gb3). Deficiency in this enzyme causes
intracellular accumulation of Gb3 and related glycosphingo-
lipids in a wide range of cell types throughout the body [1].
The major clinical manifestations include pain in the hands
and feet (acroparaesthesia), angiokeratoma, as well as renal,
cardiac, and cerebrovascular disease [2].
The Fabry Outcome Survey (FOS; sponsored by Shire)
[2], and Fabry Registry (sponsored by Genzyme) [3-5]
are databases established to collect longitudinal data on
Fabry disease. These databases have shown a long delay
between the onset of initial symptoms and a diagnosis.* Correspondence: stephenwaldek@yahoo.co.uk
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article, unless otherwise stated.For example, within the Fabry Registry, median ages for
initial onset of symptoms and a diagnosis were 9 and
23 years in males, and 13 and 32 years in females, re-
spectively [3]. Many paediatric patients (aged <19 years)
with Fabry disease report early symptoms. At enrolment
in the Fabry Registry (median age, 12 years; n = 352),
77% of males and 51% of females had symptoms or signs
of Fabry disease, including some patients who had
already developed stage-2 or -3 chronic kidney disease
(CKD; n = 3) [4]. Assessment of the renal morphological
changes in Fabry disease using light microscopy and
electron microscopy in 9 symptomatic paediatric pa-
tients (7 males, 2 females; 7–18 years) revealed glomeru-
lar and vascular changes despite normal renal function
[6]. The combination of acroparasthesia, mild albumin-
uria, glomerular endothelial cell deposits, and arterio-
pathy may indicate a more severe phenotype [6].
Classically affected males with Fabry disease develop
overt proteinuria and progressive renal impairment by
the second-to-fifth decades of life [5]. Females withCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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involvement. Among adult females with estimated glom-
erular filtration rate (eGFR) data (n = 638), 62.5% had
an eGFR <90 ml/min/1.73 m2 and 19.0% had an
eGFR <60 ml/min/1.73 m2 [5]. Approximately 30–35% of
females with Fabry disease have proteinuria [7,8], 13%
have stage 3 CKD [9] and 1–4% have end-stage renal
disease (ESRD) [5,10].
A wide range of renal histopathology is found in Fabry
disease [11]. All cell types within the kidney are affected,
even in patients with normal GFR and minimal protein-
uria [12]. Vacuolization of podocytes and epithelial cells
is characteristic of Fabry disease, with mesangial expan-
sion and progressive segmental and global glomerulo-
sclerosis also observed [12-15]. It is becoming increasingly
clear that podocytes have an important role in proteinuria.
In a study of renal histology conducted prior to enzyme
replacement therapy (ERT) in 14 young patients (age
range: 4–19 years), podocyte Gb3 inclusion volume
and density was shown to increase with age [16]. Podo-
cyte foot process width also increased with age and was
directly correlated with proteinuria. In the same study,
endothelial fenestrations were reduced, indicating a central
role for podocytes in the development and progression of
Fabry nephropathy [16]. Additionally, accumulation of Gb3
in tubular cells in the distal tubule and loop of Henle may
also contribute to some of the early renal symptoms of
Fabry renal disease [17,18].
The pathogenesis of Fabry renal disease is not fully
understood and is likely to be multifactorial (Figure 1).Gb3 accumulates in lysosomes
Lysosomal function reduced
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Figure 1 Pathogenesis of Fabry nephropathy. Gb3,
globotriaosylceramide; lyso-Gb3, globotriaosylsphingosine.Progressive intracellular accumulation of Gb3 leads to
cellular changes and histological damage. Deposition of
Gb3 can promote vascular smooth muscle cell prolifera-
tion and the release of mediators involved in the pathogen-
esis of other nephropathies [19]. Other factors considered
to be involved in the pathophysiology are the rupture of
the lysosome [20] and damage due to local inflammation
[21]. Furthermore, addition of Gb3 to cultured endothelial
cells has been found to increase oxidative stress as demon-
strated by an increase in reactive oxygen species and up-
regulation of the expression of cell adhesion molecules
[22]. Vasculopathy has also been observed in patients with
Fabry disease that may be due to the local up-regulation of
the renin–angiotensin system (RAS) [23].
Glomerular sclerosis and tubulo-interstitial fibrosis are
the histological features that best correlate with the pro-
gression of renal disease in humans with Fabry disease
[24]. As already mentioned, accumulation of Gb3 in podo-
cytes plays an important role in the pathogenesis of glom-
erular damage. A human podocyte model of Fabry disease
was developed using RNA interference to reduce alpha-
galactosidase A expression. Accumulation of Gb3 was
accompanied by an increase in autophagosomes, suggest-
ing that deregulated autophagy pathways have some
involvement in the pathogenesis of glomerular damage
in Fabry disease [25].
Progression to ESRD results in the need for renal re-
placement therapy (RRT) [26]. The extra-renal manifes-
tations of Fabry disease persist in patients receiving RRT
[27]. Renal failure increases the risk of cardiovascular
events and, consequently, those who develop ESRD are
at a greater risk of experiencing cardiovascular events
and strokes than patients with Fabry disease overall [8].
Indeed, cardiovascular disease is the most common
cause of death in patients with Fabry disease [28].
Diagnosis and assessment of Fabry nephropathy
The American College of Medical Genetics and the Na-
tional Society of Genetic Counselors have issued guide-
lines on the diagnostic confirmation of lysosomal storage
disorders, including Fabry disease [29]. Enzymatic analyses
of dried blood spots allow population screening and an
initial diagnosis in males [30], whilst in heterozygous fe-
males, in whom alpha-galactosidase A activity is highly
variable, genotyping is essential for a diagnosis. Genotyp-
ing can also be useful in male patients to assist with tra-
cing family history of the disease. Urine microscopy may
be clinically useful in diagnosing Fabry disease: vacuolated
epithelial cells, filled with glycosphingolipids, giving the
appearance of a ‘Maltese cross’, can be seen using polar-
ized light microscopy [31]. Assessment of renal Fabry dis-
ease involves several assessments and tools (Table 1), with
renal biopsy being particularly important to assess and
monitor disease progression long term [32]. It has been
Table 1 Recommendations for the management of Fabry renal disease in adults
Recommendations
Diagnosis and assessments
Confirm diagnosis • Confirm presence of Fabry disease (by enzyme analysis in males and by gene mutation studies in females)
• GFR <90 ml/min/1.73 m2 (CKD stage 1–5)
• Proteinuria: >30 mg/day or >30 mg/g creatinine (albuminuria); >300 mg/day or >300 mg/g creatinine (proteinuria)
• Other renal conditions excluded rigorously (even if a renal biopsy is needed to make that exclusion)
Kidney biopsy • Histological injury can precede clinical signs, and provides a compelling indication for institution of ERT, especially
in children and young adults
• Excludes other conditions (especially in patients with atypical presentations)
• Confirms the diagnosis and stage and can be used to assess response to therapy
Initial assessment and follow-up • Measure serum creatinine and use CKD-EPI equation to estimate the GFR
• Use iohexol plasma clearance or isotopic methods (depending on local availability) for precise measurement
of the GFR if the eGFR >60 ml/min/1.73 m2
• Standard CKD assessment schedule
• Quantify urinary albumin and protein levels
• Calculate eGFR slope
Treatment
ERT • Agalsidase alfa or beta at approved dose
• Start ERT as soon as the definitive diagnosis has been made in patients with little or no residual enzyme activity
• Start ERT as soon as the definitive diagnosis has been made in patients with residual enzyme activity if there
is evidence of kidney involvement
• ERT will not reduce proteinuria (in adults)
Control of proteinuria • Use ACE inhibitors and/or ARBs in addition to ERT
• Titrate doses to achieve urine protein <500 mg/day, even if blood pressure <130/180 mmHg
• Effects on progression are likely to occur only in the setting of optimal ERT dosing
Other therapy • All other aspects of standard CKD care apply to the management of Fabry renal disease
ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; CKD: chronic kidney disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration;
eGFR: estimated glomerular filtration rate; ERT: enzyme replacement therapy; GFR: glomerular filtration rate.
Adapted and republished with permission of American Society of Nephrology, from [Enzyme replacement therapy and Fabry renal disease. Warnock DG et al. Clin
J Am Soc Nephrol 5: 2010]; permission conveyed through Copyright Clearance Centre, Inc. [34].
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uct of Gb3 metabolism, is elevated in male patients with
Fabry disease and that it can be a useful marker in second-
ary screening to differentiate mutations of the alpha-
galactosidase A gene causing Fabry disease from those
not causing disease [33].
A new classification for Fabry disease has recently
been proposed based on the functional characterization
of GLA mutations. Lucas et al. correlated enzyme ac-
tivity levels with specific mutational effects on the en-
zyme’s three-dimensional structure and the resulting
alteration in function. It has been proposed that this
classification will facilitate the diagnosis of Fabry dis-
ease, especially when combined with biomarker data
such as lyso-Gb3 levels [35]. The proposed system of
classification may help with the so-called late onset
single organ phenotypes, some of which may not be
clinically insignificant.Progression of renal disease
In Fabry disease, the decline in renal function over time
is related to the degree of proteinuria and, in untreated
patients, is more rapid when the eGFR is below 60 ml/
min/1.73 m2. Male sex and hypertension are also signifi-
cant risk factors for development of renal failure [36]. As
with all nephropathies, protein overload may cause an
increase in the levels of inflammatory mediators, and
interstitial accumulation of these mediators may lead to
renal scarring. In patients with undiagnosed Fabry renal
disease, a significant number of glomeruli may already
be sclerotic [37]. Reduced nephron mass thus increases
the risk of further renal damage from hyperfiltration,
proteinuria, and activation of angiotensin II [37].
Consequently, regular, reproducible estimates of renal
function are essential in the management of Fabry dis-
ease. Most centres now use the eGFR calculated using
the MDRD (modified diet in renal disease) equation to
Waldek and Feriozzi BMC Nephrology 2014, 15:72 Page 4 of 13
http://www.biomedcentral.com/1471-2369/15/72assess renal function during follow-up [38]. There are
limitations to current GFR estimates [39] and the CKD-
EPI (Chronic Kidney Disease Epidemiology Collabor-
ation) equation is recommended in adults. In children, a
CKD-EPI equation developed by Schwartz et al. has
been used successfully [40]. GFR can be measured more
accurately using the iohexol plasma disappearance curve
[40]. Rombach and colleagues suggest that the Stevens’
equation (a creatinine- and cystatin C-based formula) is
also helpful, although it is recognized that cystatin C is
not uniformly available [39].
Proteinuria
Proteinuria is an early sign of Fabry renal disease in both
sexes and is often the most frequent clinical manifest-
ation [5,6]. Importantly, proteinuria is an independent
risk factor affecting the extent of renal decline in treated
and untreated patients, as well as determining the suc-
cess of ERT [41-44].
Among patients in the FOS, proteinuria was present in
44–54% of males and 33–41% of females for whom renal
data were available [45]. Similarly, data from 1,262 adult
patients (585 males, 677 females) in the Fabry Registry
demonstrated overt proteinuria (>300 mg/day) in 43% and
26% of males and females with CKD stage 1, respectively,
with higher proportions in patients with more advanced
kidney involvement [8]. Consequently, proteinuria should
be monitored regularly and treated appropriately.
Renal biopsy
Renal biopsy is useful in all patients with any degree of
proteinuria/albuminuria and/or renal dysfunction to as-
sess the degree of glomerulosclerosis and interstitial
damage because of their prognostic significance [2]. In
patients with minimal proteinuria and normal renal
function, biopsy can also determine if there is signifi-
cant Gb3 deposition (especially in podocytes and endo-
thelial cells), or early damage to indicate ERT use. In
the classical male patient with signs of renal involve-
ment a renal biopsy can be helpful in providing evi-
dence of prognosis depending on the degree of glomerular
sclerosis [41]. In females with even the slightest evidence
of Fabry nephropathy, renal biopsy is considered much
more important (and by some mandatory) as the presence
of significant renal Gb3 deposits is an indication for initiat-
ing ERT. Renal biopsy should also be undertaken if there is
the possibility of double pathology (e.g. diabetes or other
glomerular diseases such as immunoglobulin A [IgA] ne-
phropathy or thin membrane disease if haematuria is
present) and if there is a sudden, unexplained decline in
renal function [46,47].
Fabry disease can be difficult to diagnose solely from
standard light microscopy, so semi-thin toluene blue
sections or electron microscopy should be performedparticularly if there is doubt about the histological diag-
nosis [13]. The role of re-biopsy is still undetermined,
especially for evaluating the results of ERT. However, a
study by Tondel et al. found comparing deposition of
Gb3 in glomerular cells from renal biopsies taken at
baseline and after 5 years of ERT to be useful in asses-
sing the success of ERT [32]. It is better to compare
Gb3 deposition using semi-thin toluene-blue stained
sections and/or electron microscopy, rather than with
haematoxylin and eosin or periodic acid Schiff stained
slides, where the Gb3 deposition is dissolved by sol-
vents during processing of the samples. Figure 2A il-
lustrates how foam cells observed with haematoxylin
and eosin staining could be confused with other causes
of glomerular nephritis. Typical Fabry lesions observed
with toluene-blue staining or electron microscopy are
shown in Figures 2B–E.
Renal ultrasound and haematuria
Multiple renal cysts, mostly parapelvic, can be detected
using ultrasonography in up to 50% of cases of patients
[48]. Although uncommon, haematuria may also occur,
but other causes must be excluded [46,47]. The aetiology
of cysts is unknown, but the cause of haematuria is simi-
lar to that found in other glomerular diseases.
Hypertension
In the FOS Registry, a high prevalence (57% of male and
47% of female patients) of uncontrolled hypertension
was reported in patients with Fabry disease which gener-
ally increased with worsening CKD stage [49]. Similarly,
in the Fabry Registry, hypertension (systemic blood pres-
sure [BP] ≥130/80 mmHg) was observed more often in
those with poor renal function (67% vs 48% of patients
with eGFR ≥60 ml/min/1.73 m2) [8].
In general, the BP of patients with Fabry disease is
lower than that of the general population, predominantly
due to the effects of autonomic dysfunction on cardiac
and vascular function [50], although the aetiology of this
effect is complex and other factors may be involved.
Consequently, the current target for controlling hyperten-
sion in the general population (systolic BP <130 mmHg or
diastolic BP <80 mmHg) may be too high. Mainten-
ance of a BP <125/75 mmHg in patients with protein-
uria levels >1 g/day, and <130/80 mmHg in patients
with proteinuria of 0.25–1 g/day has been advocated in
CKD [37]. Caution is recommended in reducing BP <100/
70 mmHg because this has been shown to increase the
risk of cardiovascular and/or renal events [31,51,52].
Management of Fabry renal disease
ERT in Fabry disease
Two ERT products are available for treating Fabry dis-




Figure 2 Histological diagnosis of Fabry disease. (A) Haematoxylin and eosin stain of tissue from a patient with Fabry disease showing lesions
that could be confused with other conditions in which foam cells are present; (B) Semi-thin section stained with toluene blue (the preferred
method for diagnosing Fabry disease on renal histology); (C) deposits in the tubules that can give rise to mild renal tubular disorders; (D) a small
artery with large degrees of narrowing due to Gb3 deposits; (E) ultrastructural image (electron microscopy) of the glomerulus in Fabry disease
shows lamellated lipid inclusions (zebra bodies) within the podocyte cytoplasm (×6,000; stain: UrPb). Reproduced with the permission of Dr.
Kostas Giannakakis (Laboratory of Ultrastructural Pathology, Rome La Sapienza University, Rome, Italy). E, eosin; H, haematoxylin; UrPb, uranyl lead.
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agalsidase beta (Fabrazyme®, Genzyme), produced in Chin-
ese hamster ovary (CHO) cells [54]. The recommended li-
censed dose for agalsidase alfa is 0.2 mg/kg/2 weeks and is
1 mg/kg/2 weeks for agalsidase beta.
Current UK guidelines for the management of Fabry
disease state that, “No trial has yet addressed the ap-
propriate starting time of treatment or the group of pa-
tients most likely to benefit from therapy. However this
is a chronic, progressive disorder. The aim of treatment
is to prevent progression and where disease is already
manifest to try and reverse or stabilise the disease. It is
anticipated that treatment will be most successful when
started early in the course of the disease. Conversely
treatment late in the course of the disease may have
limited efficacy.” [38]. Therefore ERT should be started
as soon as symptoms/signs occur in an effort to
stabilize (or even reverse) pathology. In the UK, ERT
treatment is indicated in patients with Fabry diseasewho have evidence of renal disease (defined as an
eGFR <80 ml/min, proteinuria >300 mg/day) and/or
microalbuminuria if a renal biopsy shows endothelial
deposits [38,51].
ERT has been shown to improve the clinical outcome of
patients with Fabry disease, including stabilization of kid-
ney function and reduction in neuropathic pain [41,55-57].
However, because of the heterogeneous disease presenta-
tion, no evidence is available to support the optimal timing
of ERT or to identify the patient groups in whom disease is
likely to be most rapidly progressive or which patients are
most likely to gain significant benefit from therapy [58].
Data from the FOS have been used to develop an age- and
sex-adjustment of the global Mainz Severity Score Index
for Fabry disease. This scoring system corrects for the im-
pact of age and sex on severity. By allowing meaningful
comparisons across age and sex [59] it may be possible to
determine clinical features that predict future disease
severity.
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organ-specific (cardiac, renal, and neurological) and com-
posite prognostic severity scores [58]. Using the analysis it
was possible to differentiate groups of patients with differ-
ent outcome probabilities. The overall composite score,
the Fabry International Prognostic Index (FIPI), distin-
guished two distinct groups in whom the 50% event-free
survival differed by 10 years. The FIPI should prove to be
a valuable tool in comparative analyses of outcomes using
different therapies [58]. Additionally, a validated disease
severity scoring system for Fabry disease has been devel-
oped (DS3) to quantify disease burden and monitor dis-
ease progression and response to treatment [60].Impact of ERT on renal function
Data on the renal effects of agalsidase alfa and beta mostly
originate from open-label and observational studies, includ-
ing the FOS and the Fabry Registry [41,45,51,55,61-64],
with randomized, long-term, controlled data being limited
to one placebo-controlled trial [44] and two studies that
utilized historical controls [65,66]. Although registries can
provide long-term data on large patient populations, they
are limited by their voluntary nature, which can result in
incomplete follow-up data [67].Short-term studies
The renal benefits of ERT at tissue and clinical levels were
demonstrated in a double-blind, randomized, placebo-
controlled study of 26 patients given agalsidase alfa at
0.2 mg/kg/2 weeks for 6 months [55]. Significant improve-
ments were seen in renal structure (increase in the per-
centage of mesangium) in patients receiving agalsidase
alfa compared with placebo [55].
Similarly, agalsidase beta 1 mg/kg/2 weeks resulted in
stabilization of the GFR with rapid, marked, reductions
in plasma and tissue Gb3 observed by biochemical and
histological means [61]. A randomized, double-blind,
placebo controlled Phase IV trial investigating the effects
of agalsidase beta (1 mg/kg/2 weeks for up to 35 months
[mean, 18.4 months]) on clinical outcomes in 82 adult pa-
tients with advanced Fabry disease and mild-to-moderate
renal dysfunction found an increased time to first clinical
event and stabilized renal function compared with placebo
when adjusted for the degree of proteinuria [44].
Analyses of data from the FOS showed improvements
in renal function based on 1,040 serum creatinine meas-
urements in 201 patients [63]. Time on agalsidase alfa
therapy was an independent predictor of serum creatin-
ine levels (inverse association, p = 0.04; multivariate anal-
yses). In patients with CKD stage 2 and 3, ERT halted
the progressive decline in renal function within the first
year of treatment (longitudinal analyses) [63].Long-term studies
The benefits of ERT with agalsidase beta over 54 months
have also been reported: 41 patients with <50% glomer-
ulosclerosis and ≤1 g proteinuria per 24 hours at base-
line showed stable renal function [41].
Long-term positive results with ERT were confirmed
in an analysis of renal function in a cohort of males and
females (n = 150) in FOS receiving agalsidase alfa and
adjunctive therapies for up to 5 years [68]. Annualized
rates of decline by CKD stages are shown in Figure 3.
Responder analysis showed normalization of the eGFR
in 68.8–89.1% of those in CKD stages 1–3. The role of
agalsidase alfa in preserving renal function is also
supported by pooled data from three prospective, ran-
domized, placebo-controlled trials and their open-label ex-
tension studies involving 108 adult male patients treated for
1–4 years [56]. The rate of eGFR loss in patients with a base-
line eGFR of 30–135 ml/min per 1.73 m2 was less than that
seen during the placebo period. Multivariate analyses re-
vealed that the eGFR and proteinuria (<1 or ≥1 g/day) at
baseline significantly predicted the rate of decline of the
eGFR during treatment (Figure 4).
Renal function was evaluated in 151 men and 62
women from the Fabry Registry receiving agalsidase beta
at 1 mg/kg/2 weeks for at least 2 years [51]. Multivariate
logistic regression analyses were used to identify factors
associated with the progression of renal disease. The risk
factor most strongly associated with such progression
was an averaged urinary protein:creatinine ratio ≥1 g/g
and delays in treatment initiation compared with symp-
tom onset.
In the latest long-term study on ERT effectiveness,
renal function was assessed in 208 patients (mean time
on ERT, 7.4 years). The mean yearly change in eGFR
was −2.2 ml/min/1.73 m2 in men and −0.7 ml/min/
1.73 m2 in women [62]. In another study by Tondel et al.,
which monitored the effects of ERT in 12 patients over
5 years using serial renal biopsies, ERT was associated
with the clearance of Gb3 deposition from glomerular
cells, especially in those receiving high doses of ERT.
However, this study was carried out in a small number
of patients and these results need to be confirmed in a
larger study [32]. It also has been suggested that clear-
ance of Gb3 from podocytes may be affected by hetero-
geneity between patients in the expression levels of
receptors (mannose-6-phosphate receptor, sortilin and
megalin) that are responsible for the uptake of alpha-
galactosidase A into the lysosomes of podocytes [71].
Early intervention with ERT may preserve renal function
Patients with impaired renal function have a less favourable
outcome than those without renal impairment. A 2-year,
open-label study of 26 patients with Fabry disease treated























































































Figure 3 Change in eGFR in patients with Fabry disease and CKD during treatment with agalsidase alfa. Republished with permission of
Elsevier, from [Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Mehta A et al. Lancet
374: 2009]; permission conveyed through Copyright Clearance Centre, Inc. [68]. Data are plotted according to baseline stage of CKD. Patient
numbers are shown in parentheses. Data from previous studies for the expected natural fall in renal function in patients with Fabry disease and
the effects of agalsidase beta are plotted for reference and comparison. *[69]; †[70]; ‡[18]; §[41]; ¶[63]; ||[26]. CKD, chronic kidney disease; GFR,
glomerular filtration rate.
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[72]. All clinical endpoints (cerebrovascular and cardiac
events, renal failure, and death) occurred in patients with
impaired renal function. Despite ERT, renal function dete-
riorated and left ventricular posterior wall thickness
(PWT) was unaltered. In contrast, patients without renal
impairment at baseline had a more favourable outcome
post-treatment (no clinical events, renal function






























Figure 4 GFR during agalsidase alfa treatment in male patients with F
permission of American Society of Nephrology, from [Agalsidase alfa and k
2009; 20: 2009]; permission conveyed through Copyright Clearance Centre,Similarly, in a multivariate logistic regression analysis
of renal function from 151 men and 62 women from the
Fabry Registry who received agalsidase beta (1 mg/kg/
2 weeks) for at least 2 years, adults with Fabry disease
were at risk of progressive reduction in the eGFR despite
ERT if the urinary protein:creatinine ratio was ≥1 g/g
[51]. Men with little urinary protein excretion and those
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abry disease (stratified by baseline GFR). Republished with
idney dysfunction in Fabry disease. West M et al. J Am Soc Nephrol
Inc. [56]. GFR, glomerular filtration rate.
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strong case for early intervention because ERT seems
less effective in more advanced disease [51,72]. Two stud-
ies evaluating the occurrence of significant negative clinical
events (renal, cardiac or neural) provide further support
for starting ERT early. In a prospective study of 75 patients
undergoing ERT, prolonged ERT delayed the occurrence of
complications [65]. The difference between treated and
non-treated patients only became obvious after at least
4 years of ERT, which suggests that the risk of complica-
tions decreases with increasing treatment duration. These
data also indicated that in patients affected by Fabry
disease-related complications, ERT is unlikely to modify
outcome. In another prospective study of 40 patients
undergoing ERT and 40 matched untreated patients, no
differences in the occurrence of renal, cardiac, or neural
complications were observed between the cohorts. The
authors suggested that a long period of ERT is required to
evaluate the results but that in advanced stages of the dis-
ease ERT can improve symptoms but not slow down the
progression. However, from a nephrological point of view,
it is worth noting that the incidence of renal failure was
lower in the ERT cohort than in the comparator cohort
(10% versus 28%, respectively) [66].
The renal effects of ERT in different disease stages
have also been analysed in a meta-analysis of six studies
with a mean follow-up of 5 years [67]. This analysis
demonstrated a smaller mean decline in renal function
in males treated with ERT than in untreated males when
the GFR was <60 ml/min/1.73 m2. However, in males
with a baseline GFR of >60 ml/min/1.73 m2 and in
females the decline in renal function was comparable be-
tween the ERT and untreated groups.
Although there is limited long-term, controlled evi-
dence of a clinical benefit of ERT on renal function, we
feel that there is adequate, less rigorous evidence to indi-
cate that ERT is of benefit, especially when started early
in the course of the disease. However, to optimize the
results from ERT, it should be used, when appropriate,
with other adjuvant therapies.
Long-term safety of ERT and antibody formation
Long-term ERT can be associated, mostly in male patients,
with the occurrence of antibodies against the infused en-
zyme [73]. While there are problems in interpreting anti-
body levels and comparing them between the two products
due to differences in measurement methodologies and “cut
off” points [73], some potentially useful data are available.
IgG antibodies occur with both products, but seem to be
generally higher with agalsidase beta [73]. In an open-label
extension study of agalsidase beta, infusion-related reac-
tions (rigors, temperature-change sensation, fever, nausea,
headache and nasal congestion) were the most common
enzyme-related adverse events [74]. With the exception ofone patient, all the reactions were mild and decreased over
time, similar to observations reported from the FOS regis-
try 5-year follow up [68]. The initial increase in frequency
of infusion-related reactions seems to parallel the serocon-
vertion rate [41]. Although high antibody titres to either
product could have an inhibitory effect on agalsidase A ac-
tivity in vitro, the relationship to clinical response is much
more difficult to assess [73]. Most studies reported so far
have looked at the relationship between antibody titres and
surrogate markers such as Gb3 or lyso-Gb3 in urine or
plasma [73,75]. Therefore, although the long-term effects
of antibodies on ERT have yet to be determined, the pre-
scribing nephrologist should be aware of the issues and po-
tential problems.
Dosage of ERT
The optimal dosage and regimen for ERT in Fabry dis-
ease are unclear. The licensed doses for agalsidase alfa
and agalsidase beta are 0.2 mg/kg/2 weeks and 1 mg/kg/
2 weeks, respectively. Clearance of Gb3 from podocytes
has been shown to be dose-dependent, with higher doses
associated with greater clearance [32]. Regarding frequency
of dosing, in patients demonstrating a continuing de-
cline in renal function, switching from bi-weekly dos-
ing to weekly dosing of agalsidase alfa (0.2 mg/kg) has
been found to improve eGFR, with the mean rate of
change in eGFR slowing from −8.0 ml/min per 1.73 m2/
year to −3.3 ml/min per 1.73 m2/year [69]. A recent short-
term study assessing three doses of agalsidase alfa (0.2 mg
every 2 weeks; 0.1 mg and 0.2 mg every week) showed a
trend for the higher dose to be most effective suggest-
ing a longer-term study was needed [76]. A study of
agalsidase beta involving 21 male patients receiving the
standard dose of 1 mg/kg body weight for 6 months
followed by a reduced dose of 0.3 mg/kg body weight
for a further 18 months showed that 100% of patients
cleared Gb3 by 6 months while only 70% were still
clear at 18 months [77].
From June 2009 to 2012, production and quality is-
sues led to a worldwide shortage of agalsidase beta
resulting in adult patients receiving reduced doses of
agalsidase beta (approved dose 1 mg/kg/2 weeks, re-
duced dose 0.3−0.5 mg/kg/2 weeks), or switching to
agalsidase alfa (administered dose 0.2 mg/kg/2 weeks)
[78]. In 2010, the European Medicines Agency (EMA)
focused their attention on patients treated with lower
doses of agalsidase beta noting an increase in adverse
events in these patients; specifically “a pattern of ad-
verse events resembles the natural, but accelerated,
course of Fabry disease” [78]. The effectiveness of spe-
cific ERT doses has also been evaluated in groups of
patients switched from agalsidase beta to agalsidase
alfa during this period. In 2011, Smid et al. reported
that there were no relevant clinical differences in
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agalsidase, although both patients switching to agalsid-
ase alfa (following a dose reduction of agalsidase beta)
and those who continued on a reduced agalsidase beta
dose had increased levels of lyso-Gb3 suggesting in-
creased disease activity [79]. This study also showed a
minimal but significant decrease in two of the quality
of life subscales in the SF-36 questionnaire. End-organ
damage and clinical symptoms during dose reduction
of agalsidase beta or switch to agalsidase alfa has also
been assessed in an observational study (N = 105) [80].
During a median follow-up of 12 months, predefined
measures of organ function were stable in those con-
tinuing on agalsidase beta 1 mg/kg/2 weeks. In con-
trast, there was a significant decrease in renal function
as assessed by eGFR in those receiving a reduced dose
of agalsidase beta, as well as an increase in the number
of patients experiencing pain attacks or pain crises.
There was also an increase in microabuminuria and
Fabry disease-related symptoms (pain aggravation and
gastrointestinal symptoms) among patients switching
to agalsidase alfa. Considering all data published on
the clinical effects of agalsidase alfa, it is surprising
how in this report the patients treated with agalsidase
alfa had such a significant worsening of their symp-
toms in such a short time.
In other studies from Japan [81] and Italy [82] no clin-
ical and/or laboratory differences (Gb3 levels) were ob-
served after the switch from agalsidase beta to agalsidase
alfa. Similar results were reported for a cohort of 40 pa-
tients in Australia although lower energy levels were ob-
served in the male patients [83]. It is important to
emphasize that all the studies on switching from agal-
sidase beta to agalsidase alfa were carried out in a
small number of patients and for short periods of time
(<2 years).
Adjunctive therapy for proteinuria and cardiovascular
disease
Reduction of proteinuria using drugs inhibiting the RAS is
an essential and potent tool for improving renal outcome
in patients with Fabry disease with CKD. Angiotensin-
converting enzyme (ACE) inhibitors and angiotensin-II re-
ceptor antagonists (ARBs), have been demonstrated to be
renoprotective in chronic nephropathy [37]. Protein levels
can be reduced with ACE inhibitors/ARBs to <0.5 g/day,
and are associated with significant stabilization of renal
glomerular function [36,84]. Care should be taken to ti-
trate doses to avoid hypotension [34,51,52]. The additional
cardioprotective action of RAS inhibitors provides a fur-
ther rationale for their use in patients with CKD [37].
These drugs will help control BP and are important for
preserving renal function. Management should also in-
clude lipid-lowering and anti-platelet agents as indicated,together with appropriate prophylaxis against stroke [38].
Additionally, since cardiac arrhythmias do not respond to
ERT, care should be taken to detect arrhythmias, as such
events can lead to sudden cardiac death, particularly in
women [9,85].
Dialysis and transplantation
Survival of patients on dialysis with Fabry disease and
ESRD is poor. Three-year survival has been shown to be
60% in Europe [86] compared with 63% in the USA [87].
Although this was better than 3-year survival in a dia-
betic control population (53%), it was significantly lower
than in the non-diabetic control group (74%) [87]. This
is almost certainly due to the added disease burden from
the cardiovascular complications of Fabry disease [88].
Thus, ERT should be considered on an individual patient
basis in an attempt to reduce the risk of cardiovascular
events.
Renal transplantation was initially considered as a po-
tential treatment for alleviating some of the symptoms
of Fabry disease by providing a source of alpha-galactosidase
A enzyme. However, this was found not to be the case, with
circulating alpha-galactosidase A levels remaining low after
transplantation [89]. Nevertheless, the results of renal trans-
plantation in patients with Fabry disease are excellent: 5-year
graft survival has been reported as 74%, which was superior
to that of patients with ESRD due to other causes (69%), but
comparable with a matched cohort [90]. Patient survival at
5 years was 81%, which was slightly lower than that of the
matched cohort (90%) [90]. The results of this study were
comparable with those of an earlier study, in which 5-year
graft survival and 5-year patient survival were 75% and 83%,
respectively [27]. In fact, the results of renal transplantation
are so encouraging that it should be considered as the first-
line option to correct renal dysfunction in patients with
Fabry disease and ESRD [91]. However, despite the positive
data supporting renal transplantation, Fabry disease has been
shown to confer a higher risk of death versus diabetic con-
trol patients (odds ratio 2.15) [88].
There are few data on ERT in patients with ESRD, ei-
ther on dialysis or with a functioning renal transplant.
However, ERT administered to patients with ESRD on
dialysis or with a history of renal transplantation has
demonstrated a favourable safety profile and the same
dosing regimen can be used as for patients with Fabry
disease without ESRD [92]. Furthermore, there is evi-
dence that ERT can be administered during haemodialy-
sis, without loss of the enzyme in the dialysate [93].
Management of Fabry disease in women
Organ involvement occurs later in life and with a lower
prevalence in women than in men, but the signs and
symptoms of Fabry disease should be treated in women
because organ involvement is progressive and causes
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have been dedicated specifically to women with Fabry dis-
ease [94]. However, a 4-year study of agalsidase alfa
0.2 mg/kg/2 weeks in 36 symptomatic women (mean age,
47 years) highlighted its long-term effectiveness [95].Areas for further research
Chaperon molecules
An investigational therapeutic strategy, which is cur-
rently being explored, is the use of chaperon molecules
to stabilize the chemical structure of the residual agal-
sidase alfa or to prolong the half-life of the infused en-
zyme [96,97]. At present, clinical studies in Fabry patients
are very limited and as yet no licensed chaperone drugs
are available [98].Biomarkers
Biomarkers have an important role in the assessment of
disease activity and response to treatment in other lyso-
somal storage diseases. However, despite encouraging re-
search, a biomarker has yet to be identified that is
relevant to clinical outcomes in Fabry disease [67,75,99].
Nevertheless, biomarkers may play an important part as
indicators of diagnosis and when to commence therapy
in Fabry disease patients. They may also be useful in de-
termining the progression of Fabry disease. Urinary pro-
tein and albumin excretion are the most important
biomarkers of Fabry disease nephropathy [36,44]. Urin-
ary Gb3 levels are consistently elevated in most patients
with Fabry disease (although marked inter-patient vari-
ability has been observed). Urinary Gb3 levels decrease
during ERT in men, women, and children with Fabry
disease. However, despite this response, urinary Gb3
cannot be considered to be a suitable biomarker of
clinical efficacy because baseline levels do not correlate
with disease severity, and do not predict clinical effi-
cacy [100].
Recently, plasma [101] and urinary [102] lyso-Gb3
have been identified as new potential biomarkers. In a
study of 10 male and 8 female patients with Fabry dis-
ease, plasma lyso-Gb3 was increased in males, and was
higher in cases of the classic form of Fabry disease than in
variant Fabry hemizygotes [101]. In females, plasma lyso-
Gb3 was moderately increased in symptomatic and asymp-
tomatic cases, with a correlation between the increase in
plasma lyso-Gb3 and decrease in alpha-galactosidase A ac-
tivity. Lyso-Gb3 analogues were also isolated in the urine of
63 patients with Fabry disease [102]. Increased urinary ex-
cretion of lyso-Gb3 in patients with Fabry disease cor-
related well with several indicators of disease severity, and
may be a reliable independent biomarker for the clinically
important characteristics of Fabry disease. However, there
was no correlation between urinary lyso-Gb3 and eGFR.Therefore, one cannot assume that lyso-Gb3 is a reliable
biomarker of renal involvement [101].
In 2012, Rombach et al. confirmed elevated levels of
lyso-Gb3 in the plasma and/or urine of patients with
Fabry disease and described a reduction of plasma levels
of lyso-Gb3 after 1 year of ERT [75]. This decline in lyso-
Gb3 was associated with a reduction in left ventricular
mass in females and a lower risk of developing white mat-
ter lesions in the nervous system for both sexes [75]. Re-
cently, new potential biomarkers, Gb3 analogues, have
been identified in the plasma of untreated male Fabry
disease patients, but their clinical meaning still has to
be validated [103].
The utility of Cystatin C as a biomarker in Fabry dis-
ease has also been evaluated [104]. In an observational,
multicentre study of 89 patients (n = 42 females; n = 47
males) with Fabry disease and varying degrees of disease
severity, serum Cystatin C levels were measured. The
authors concluded that Cystatin C is a good and cost-
effective prognostic indicator of early renal dysfunction
and/or heart failure in Fabry disease [104].
Urinary uromodulin excretion has been examined in
15 male patients with Fabry disease [105]. In untreated
patients, changes ranged from a normal to marked de-
crease or absence of urinary uromodulin frequently ac-
companied by aberrantly processed uromodulin. These
patterns normalized in all patients on ERT and some on
substrate reduction therapy. This suggests that uromod-
ulin may also be a potential biochemical marker of renal
therapeutic response to ERT.
Urine proteomic analysis based on capillary electro-
phoresis coupled to mass spectrometry has recently been
used to identify a biomarker profile in patients with
Fabry disease [106]. In 35 treatment-naïve adult female
patients with Fabry disease an abnormal urine profile
was identified, which was almost completely corrected
following ERT [106]. A further two protein biomarkers
have been identified in the urine of children with Fabry
disease and type-1 diabetes using label-free quantitative
proteomics. Prosaposin and ganglioside GM2 activator
protein were significantly elevated in patients with Fabry
disease and ERT was associated with a significant reduc-
tion in urinary excretion of these proteins. Therefore,
these urinary biomarker models may useful as diagnostic
tools for patients with Fabry disease, as well as for moni-
toring response to ERT [107]. However, there is still
work to be done to identify a biomarker that truly re-
flects disease activity and progression, as well as enab-
ling responses to ERT to be measured.
Conclusions
Fabry disease should be considered in the differential
diagnosis of proteinuria of uncertain origin to ensure an
early diagnosis. Proteinuria is a risk factor for the
Waldek and Feriozzi BMC Nephrology 2014, 15:72 Page 11 of 13
http://www.biomedcentral.com/1471-2369/15/72progression of renal disease and should be managed ap-
propriately. Early detection of renal involvement should
be achieved by regular measurement of GFR and urine
protein excretion in all patients, male and female, using
renal biopsy where indicated. Biomarkers play an im-
portant part in the assessment of disease activity and re-
sponse to treatment in other lysosomal storage diseases,
and could potentially aid the diagnosis and management
of Fabry renal disease.
Early intervention with ERT may help stabilize renal
function or slow its decline, when used as part of a com-
prehensive management strategy to prevent complica-
tions of Fabry disease. Although there are currently limited
long-term, controlled effectiveness data, ERT with agalsi-
dase alfa or beta has been shown to reduce the decline in
renal function in short- and long-term studies in male, fe-
male, and paediatric patients.
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